{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:21:28Z","timestamp":1787062888465,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ejca.2017.10.007","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T10:01:18Z","timestamp":1509444078000},"page":"10-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Recurrence dynamics of breast cancer according to baseline body mass index"],"prefix":"10.1016","volume":"87","author":[{"given":"Elia","family":"Biganzoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Desmedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Fornili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cornez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernand","family":"Ries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Closon-Dejardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Focan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Di Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Nogaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Sotiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Demicheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.10.007_bib1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","article-title":"Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants","volume":"387","author":"(NCD-RisC) NCDRFC","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2017.10.007_bib2","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2013viewpoint of the IARC working group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.10.007_bib3","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1200\/JCO.2016.68.4480","article-title":"Obesity and breast cancer prognosis: evidence, challenges, and opportunities","volume":"34","author":"Jiralerspong","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.007_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-009-0512-0","article-title":"The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial","volume":"119","author":"de Azambuja","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2017.10.007_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF01807163","article-title":"Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy","volume":"41","author":"Demicheli","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2017.10.007_bib6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10549-008-0022-5","article-title":"Time-varying pattern of recurrence risk for Chinese breast cancer patients","volume":"114","author":"Yin","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2017.10.007_bib7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1158\/1055-9965.EPI-11-1089","article-title":"Hazard of recurrence among women after primary breast cancer treatment \u2013 a 10-year follow-up using data from SEER-Medicare","volume":"21","author":"Cheng","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejca.2017.10.007_bib8","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1186\/bcr3559","article-title":"Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index","volume":"15","author":"Ribelles","year":"2013","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.007_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ncponc0999","article-title":"Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures","volume":"4","author":"Demicheli","year":"2007","journal-title":"Nat Clin Pr Oncol"},{"key":"10.1016\/j.ejca.2017.10.007_bib10","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/bcr2152","article-title":"Recurrence dynamics does not depend on the recurrence site","volume":"10","author":"Demicheli","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.007_bib11","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","article-title":"Annual hazard rates of recurrence for breast cancer after primary therapy","volume":"14","author":"Saphner","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.007_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1006133418245","article-title":"Time-dependence of hazard ratios for prognostic factors in primary breast cancer","volume":"52","author":"Hilsenbeck","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2017.10.007_bib13","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2000.18.14.2702","article-title":"Time-dependent relevance of steroid receptors in breast cancer","volume":"18","author":"Coradini","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.007_bib14","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdg422","article-title":"Prognosis in node-negative primary breast cancer: a neural network analysis of risk profiles using routinely assessed factors","volume":"14","author":"Biganzoli","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.10.007_bib15","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/jnci\/djt134","article-title":"Prospective observational study of breast cancer treatment outcomes for UK women aged 18\u201340 years at diagnosis: the POSH study","volume":"105","author":"Copson","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.10.007_bib16","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","article-title":"Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V","volume":"34","author":"Colleoni","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.007_bib17","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1200\/JCO.2001.19.12.3103","article-title":"Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer","volume":"19","author":"Piccart","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.007_bib18","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.007_bib19","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/j.ejca.2015.08.011","article-title":"Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy","volume":"51","author":"de Azambuja","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.10.007_bib20","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1200\/JCO.2008.17.2155","article-title":"Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study","volume":"27","author":"de Azambuja","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.007_bib21","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(11)70231-5","article-title":"HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data","volume":"12","author":"Di Leo","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.10.007_bib22","series-title":"Report of a WHO Expert Consultation: World Health Organization Technical Report","author":"Organization WH","year":"1995"},{"key":"10.1016\/j.ejca.2017.10.007_bib23","series-title":"Analysing survival data from clinical trials and observational studies. In all computations the R software, version 3.3.2 (R Core Team)","author":"Marubini","year":"2016"},{"key":"10.1016\/j.ejca.2017.10.007_bib24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejca.2017.10.007_bib25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1214\/aos\/1176346152","article-title":"Smoothing counting process intensities by means of kernel functions","volume":"11","author":"Ramlau-Hansen","year":"1983","journal-title":"Ann Stat"},{"key":"10.1016\/j.ejca.2017.10.007_bib26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0167-9473(02)00122-6","article-title":"Joint modelling of cause-specific hazard functions with cubic splines: an application to a large series of breast cancer patients","volume":"42","author":"Boracchi","year":"2003","journal-title":"Comput Stat Data Anal"},{"key":"10.1016\/j.ejca.2017.10.007_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1214\/ss\/1038425655","article-title":"Flexible smoothing with B-splines and penalties","volume":"11","author":"Eilers","year":"1996","journal-title":"Stat Sci"},{"key":"10.1016\/j.ejca.2017.10.007_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2010.29.7614","article-title":"Effect of obesity on prognosis after early-stage breast cancer","volume":"29","author":"Ewertz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.007_bib29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/annonc\/mdh222","article-title":"Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience","volume":"15","author":"Berclaz","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.10.007_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/A:1006134702484","article-title":"Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of \u201ccures.\u201d","volume":"53","author":"Demicheli","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2017.10.007_bib31","first-page":"5575","article-title":"A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis","volume":"61","author":"Guba","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.007_bib32","doi-asserted-by":"crossref","first-page":"6778","DOI":"10.1158\/0008-5472.CAN-16-0608","article-title":"Inflammation triggers Zeb1-dependent escape from tumor latency","volume":"76","author":"De Cock","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.007_bib33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nature20791","article-title":"Targeting metastasis-initiating cells through the fatty acid receptor CD36","volume":"541","author":"Pascual","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.10.007_bib34","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4161\/cbt.11.10.15473","article-title":"Postmenopausal obesity promotes tumor angiogenesis and breast cancer progression in mice","volume":"11","author":"Gu","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejca.2017.10.007_bib35","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1158\/0008-5472.CAN-13-0926","article-title":"Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis","volume":"73","author":"Arendt","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.007_bib36","doi-asserted-by":"crossref","first-page":"13007","DOI":"10.1038\/ncomms13007","article-title":"Obesity-associated NLRC4 inflammasome activation drives breast cancer progression","volume":"7","author":"Kolb","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2017.10.007_bib37","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/ijc.29940","article-title":"A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis","volume":"138","author":"Nechuta","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2017.10.007_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0960-0760(94)90274-7","article-title":"Aromatase gene expression in adipose tissue: relationship to breast cancer","volume":"49","author":"Bulun","year":"1994","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ejca.2017.10.007_bib39","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0959-8049(05)80204-7","article-title":"Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast\u00a0cancer","volume":"29","author":"Thorpe","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.10.007_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4236\/ojog.2017.71014","article-title":"Chemotherapy induced amenorrhea in women treated with chemotherapy for breast Carcinoma in Yalgado Ou\u00e9draogo teaching Hospital in ouagadougou, Burkina Faso","volume":"7","author":"Bambara","year":"2017","journal-title":"Open J Obstet Gynecol"},{"key":"10.1016\/j.ejca.2017.10.007_bib41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF01834642","article-title":"Endocrine profile in breast cancer patients receiving chemotherapy","volume":"20","author":"Mehta","year":"1992","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2017.10.007_bib42","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.10.007_bib43","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/jnci\/88.24.1828","article-title":"Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group","volume":"88","author":"Tormey","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.10.007_bib44","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.10.007_bib45","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jnci\/93.6.456","article-title":"Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years","volume":"93","author":"Stewart","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.10.007_bib46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2017.10.007_bib47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Goss","year":"2016","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917313473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917313473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T18:28:28Z","timestamp":1540492108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917313473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":47,"alternative-id":["S0959804917313473"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.10.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrence dynamics of breast cancer according to baseline body mass index","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}